<DOC>
	<DOCNO>NCT01907360</DOCNO>
	<brief_summary>This study conduct 2 separate stage , first adolescent second child . Both Stages 1 2 use adaptive , single multiple cohort open-label , single-treatment , fast design examine pharmacokinetic ( PK ) effect 2 separate modify release formulation ( B C ) HLD200 ( 54 mg ) .</brief_summary>
	<brief_title>Phase I/II Single Center , Single-Treatment , Open-Label , Adaptive Clinical Trial Design Examining Pk 2 MR Formulations MPH Adolescent/Pediatric With ADHD</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>Male female adolescent ( 1317 year ; Stage 1 ) child ( 612 year ; Stage 2 ) . Previous diagnosis ADHD confirmation use Mini International Neuropsychiatric Interview Children Adolescents ( MINIKID ) . ADHD symptom control stable dose ADHD medication . Subjects MPH previous history symptom control treatment MPH . Physical examination free clinically significant finding , unless deem NCS Investigator Medical Monitor ; Able swallow treatment capsule ; Available entire study period ; Provision inform consent ( parent [ ] and/or legal representative [ ] ) assent ( subject ) ; Female subject childbearing potential ( i.e. , postmenarche ) require negative result urine pregnancy test ( give specific instruction avoid pregnancy trial ) Any known history presence significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , ophthalmologic disease , unless deem NCS Investigator Medical Monitor ; Presence significant physical organ abnormality ; Any illness 4 week study , unless deem NCS Investigator Clinical and/or Medical Monitor ; Severe comorbid psychiatric diagnosis may affect subject safety confound result ( e.g. , psychosis , bipolar disorder ) ; Known history moderate severe asthma ; Known history severe allergic reaction ( include drug , food , insect bite , environmental allergen ) ; Known history seizure ( except febrile seizure prior age 5 ) , anorexia nervosa , bulimia current diagnosis family history Tourette 's disorder ; Subject severely underweight overweight . Clinical value outside acceptable range , unless deem NCS significant per Investigator ; Positive history hepatitis B , hepatitis C Human Immunodeficiency Virus ( HIV ) ; Positive screen illicit drug use , and/or current health condition use medication might confound result study increase risk subject ; Use prescription medication ( except ADHD medication ) within 7 day overthe counter medication ( except birth control ) within 3 day precede study enrollment , unless deem acceptable Investigator Clinical and/or Medical Monitor ; Blood draw 50 ml 249 ml within 30 day , 250 ml 449 ml within 45 day â‰¥ 450 ml within 60 day precede study enrollment ; Participation clinical trial investigational drug within 30 day precede study enrollment ; Intolerance venipuncture ; Current suicidal ideation history suicidality determine significant finding ColumbiaSuicide Severity Rating Scale ( CSSRS ) investigator ( Baseline CSSRS adolescent ; Pediatric Baseline CSSRS child ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>